

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 0 704 533 A1**


(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
03.04.1996 Bulletin 1996/14

(21) Application number: 94115505.3

(22) Date of filing: 30.09.1994



(51) Int. Cl.<sup>6</sup>: **C12N 15/86**, C12N 7/00,  
C12N 15/62, A61K 39/145,  
A61K 35/76

(84) Designated Contracting States:  
**DE**

(71) Applicant: **BAYER AG**  
D-51368 Leverkusen (DE)

(72) Inventors:  
• **Hobom, Gerd Prof. Dr.**  
D-35392 Giessen (DE)  
• **Neumann, Gabriele Dr.**  
D-63447 Maintal (DE)  
• **Menke, Annete**  
D-35037 Marburg (DE)

(54) **An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus**

(57) RNA polymerase I transcription *in vivo* in transiently DNA-transfected cells has been used for expression of influenza vRNA molecules coding for chloramphenicol acetyltransferase (CAT) in anti-sense orientation. Influenza virus superinfection served to provide viral RNA polymerase and other proteins for transcriptional conversion of minus-strand vRNA into plus-strand viral mRNA molecules expressing CAT activity. This system has been used for an analysis via nucleotide exchanges as well as deletions and insertions of both terminal segments of the vRNA sequence which cooperatively constitute the vRNA promoter structure. Several mutants with greatly enhanced expression rates over wild-type levels have been constructed, which also can be packaged and serially passaged into progeny virus. The data obtained for the mutations in various promoter elements support a model of consecutive, double-strand vRNA promoter structures in binding of viral polymerase and initiation of RNA synthesis.

**EP 0 704 533 A1**

## Description

The object of the present invention was to make a vaccination virus. This objective has been fulfilled with the segmented virus described herein.

The genome of influenza A viruses consists of 8 different single-stranded viral RNA (vRNA) molecules of negative polarity, which have in common 5' and 3' terminal sequences largely complementary to each other. These conserved segments 13 and 12 nucleotides in length are known to form double-stranded RNA panhandle structures (Hsu et al., 1987; Fodor et al., 1993) which have been analysed in more detail recently *in vitro* using internally deleted model RNAs (Baudin et al., 1994; Tiley et al., 1994). In the virion the panhandle ends of all RNA segments are found in specific binding to viral RNA polymerase complexes, while the remaining internal segments stay single-stranded with viral nucleoprotein (NP) in cooperative binding (Compans et al., 1972; Honda et al., 1988; Martin et al., 1992). Upon infection these viral RNPs initially serve as templates for the synthesis of viral mRNAs by a specific cap-snatching mechanism (Plotch et al., 1979; Braam et al., 1983), and later on will direct synthesis of full-length complementary RNAs (cRNAs), probably dependent on the absence or presence of newly synthesized NP protein (Shapiro and Krug, 1988). The plus-strand cRNAs are then used as templates for progeny vRNA synthesis.

The viral RNA polymerase complex consisting of proteins PB1, PB2, and PA is involved in all three different modes of RNA synthesis during the viral replication cycle, following its specific binding to the terminal panhandle segments of both vRNAs and cRNAs. Sequence comparison reveals that the vRNA and cRNA termini have similar, but not identical sequences. For that reason vRNA and cRNA recognition may be distinguished because of these structural alterations allowing for asymmetries in initiation of plus and minus strand RNA synthesis, and possibly in viral RNP packaging, which has also been suggested to be controlled by the panhandle RNA sequence (Hsu et al., 1987).

Recently, we reported on an *in vivo* system for the introduction of specific mutations into the genome of influenza viruses: viral cDNA has been inserted in antisense orientation between mouse rDNA promoter and terminator sequences. This has been derived from *in vitro* transcription experiments based on nuclear extracts from Ehrlich ascites cells, which resulted in transcripts exactly resembling influenza vRNA. For a series of *in vivo* studies, the viral coding sequence was replaced by the coding sequence for chloramphenicol-acetyltransferase (CAT), however, with both influenza terminal non-coding sequences being retained exactly on the resulting vRNA transcripts. After transfection of this recombinant DNA template into mouse cells followed by influenza virus infection, CAT activity was detectable. Transfer of supernatants to different cells demonstrated that CAT-vRNAs transcribed *in vivo* by cellular RNA polymerase I were not only transcribed by viral RNA polymerase into plus-strand mRNA and translated into CAT protein, but also were replicated and packaged into infectious progeny virus particles (Zobel et al., 1993; Neumann et al., 1994).

We have used this system for a stepwise introduction of single and multiple mutations into the conserved panhandle RNA sequence, thereby effectively converting the HA-vRNA promoter sequence into an HA-cRNA promoter sequence and vice versa. For these series of constructs CAT activities have been measured both in primarily transfected and infected B82 cells and, after passaging of B82 supernatants, in secondarily infected MDCK cells. From the results obtained we propose a model for the terminal RNA sequence as being recognized RNA polymerase in consecutive steps of different structure when used as a template for initiation of viral mRNA synthesis.

The present invention relates to a segmented RNA virus which comprises one or more segments which have been genetically modified to show improved transcription, replication and/or expression rates.

The virus can be one where one or more modifications have been introduced in the noncoding region(s) and/or one or more modifications have been introduced in the coding region(s). A possibility is that at least one modified segment is derived from an original one by sequence variation(s). It is also possible that at least one modified segment is an artificial addition to the set of original or modified original segments. The virus can be one wherein the modified segment comprises a nucleotide sequence which codes for a protein or peptide which is foreign to the original virus. Preferred is that the foreign protein or peptide constitutes an antigen or antigen-like sequence, a T-cell epitope or related sequence. In such a case it is possible that the segment comprises repetitions of an antigen or epitope or other. Such an antigen or epitope can be derived from HIV, Herpes-Virus, Rhinovirus or CMV. The virus of the present invention may be a single stranded negative-strand RNA virus as for example one of the Orthomyxoviridae family, the Bunyaviridae family or of the Arenaviridae family. The most preferred virus is an influenza virus. The virus of the present invention can also be a double-stranded RNA virus, as for example a reovirus, a rotavirus or an orbivirus.

The present invention also relates to the virus and use of the virus for the preparation of pharmaceuticals.

### Mutational analysis of vRNA 3' terminal sequence positions.

Influenza A viral RNA 5' and 3' ends have similar, but not identical sequences with nucleotide mismatches at positions 3, 5 and 8, and an additional unpaired nucleotide is located at position 10 in the 5' region. Nevertheless, both vRNA termini hybridize into a double stranded panhandle structure made up of twelve and thirteen nucleotides in common for all eight RNA segments, plus in average three additional basepairs specific for each of the vRNA molecules. Due to the deviations mentioned the cRNA or plus strand panhandle structures have to be different from the vRNA structures;

however, both are recognized by viral RNA polymerase and are used for initiation of RNA synthesis, i.e. they are constituting a promoter structure. Even if in initial recognition and binding of RNA polymerase the double stranded RNA panhandle structure is known to be the substrate, and is also observed in virion RNPs (Hsu et al., 1987), for the initiation step of transcription at the 3' ultimate template position this terminal region has to be separated into a partially single stranded, i.e. 'forked' structure (Fodor et al., 1994). RNA polymerase may be predicted to continue its binding interaction with both, the remaining double stranded segment: nucleotides 10 to 15 versus 11 to 16<sup>1</sup>, and to the single stranded 3' template segment: nucleotides 1 up to 9, as well as the 5' single stranded end (Tiley et al., 1994). Introduction of mutations at specific positions in either strand may hence alterate simultaneously both of these consecutive vRNA promoter structures: panhandle and fork in different ways, and will in addition also result in corresponding variations of the cRNA promoter structure.

To investigate the importance of the three mismatch positions, specific single, double or triple nucleotide exchanges were first introduced into the vRNA 3' end sequence at positions 3, 5 and 8, thereby approaching a fully double-stranded vRNA promoter structure, in a step-wise manner. At the same time the vRNA 3' end template sequence will become equivalent to the cRNA 3' end in these positions, but not in regard to the additional nucleotide at position 10. Single nucleotide exchanges according to this scheme (pHL1098, pHL1099, pHL1100) abolished the promoter activity, and no CAT activity was observed, as has been reported before with a different method (Luo et al., 1993). Two of the double mutation constructs (pHL1101, pHL1103) also gave negative results.

In contrast, for pHL1102 (G3A, U8C)<sup>1</sup> a significant CAT activity was detected, distinctly higher than for the corresponding wild-type construct (pHL926;) which in the conditions applied (8 hr after infection) resulted in rather low levels of CAT expression. This activity increase is further enhanced for the final construct of this series carrying the triple exchange G3A, C5U and U8C (pHL1104), i. e. transfection of pHL1104 DNA followed by influenza virus infection resulted in a very high level of CAT expression, also considerably above the pHL1102 results.

These results have been repeated using various conditions of transfection and infection as well as determining kinetic data during the course of infection. While the pHL1104 variant is always observed far superior over any wild-type construct that expression ratio may be variable and difficult to quantitate (between around 20 fold and nearly 100 fold). Rather short infective cycles of eight hours as used prevalently appear to put more slowly replicating, i.e. wild-type molecules at a disadvantage, in particular in passaging of packaged pseudo-vRNA molecules via virus progeny, both is found increased for wildtype and related constructs after DNA transfection plus twelve hours of infection (see Neumann et al., 1994). Remaining deviations in CAT expression ratios may be attributed to variations in growth conditions in individual experiments.

#### Mutational analysis of vRNA 5' terminal sequence positions

We also addressed the question whether the unexpectedly high viral mRNA expression rate of pHL1104 is the consequence of a stabilized panhandle double-strand structure or may be directly attributed to the point mutations introduced into the vRNA 3' sequence, and active when being used as a single-stranded template segment, e.g. in the 'forked' structure.

For this purpose we constructed pHL1124, three complementary point mutations introduced at the 5' end of the vRNA sequence again in positions 3, 5 and 8 (U3C, G5A, A8G). Together wild-type vRNA 3' end of these variations again result in a panhandle structure free of mismatches and, therefore, pHL 1124 is equivalent in this regard to pHL1104, but different in the sequence of its template and non-template single strands. No significant CAT expression was detected for pHL1124. We conclude that the increased CAT activity of pHL1104 is not a consequence of the stabilized panhandle structure itself, but at least in part is a consequence of the individual nucleotide exchanges at positions 3, 5 and 8 at the 3' end of the vRNA sequence, it is also more likely then to originate from other structural intermediates of initiation than a stabilized panhandle.

#### Mutational analyses of concerted exchanges at both ends of the vRNA sequence

In order to determine in detail the influence of single, double and triple exchanges at the vRNA 5' end upon CAT expression rates we also used the improved vRNA 3' end sequences of pHL1104 and pHL1102 as starting points rather than the corresponding wild-type sequence. From the series of experiments related to pHL1104 and from the equivalent series related to pHL 1102 it can be concluded that retaining a G residue in position 5 is the most important single feature

<sup>1</sup>Notations concerning nucleotides 1 to 15 refer to positions in the vRNA 3' end, e.g. position 2 designates the penultimate nucleotide; 5' end positions are given in ordinary numbers. The notation G3A describes a mutational change of guanosine to adenosine at position 3.

<sup>1</sup>Notations concerning nucleotides 1 to 15 refer to positions in the vRNA 3' end, e.g. position 2 designates the penultimate nucleotide; 5' end positions are given in ordinary numbers. The notation G3A describes a mutational change of guanosine to adenosine at position 3.

in these 5' end variations. A single exchange into an A residue at position 5 as in pHL1185 will render the promoter entirely inactive, while single exchanges in positions 3 or 8, as well as a 3 plus 8 double exchange will retain promoter activity even if reduced from the level observed for pHL1104, but still above wild-type expression rates. While the G5A nucleotide substitution opposite nucleotide C5 in the 3' terminus results in losing one basepair (in the panhandle context) within the pHL1104 series, a basepair is indeed gained by exactly the same G5A exchange within the pHL1102 series, i.e. opposite the U5 residue as present in the pHL1102 vRNA 3' end. Since again the G5A exchange results in loss of promoter function inspite of gaining one basepair we conclude that the guanosine at position 5 may be important for RNA polymerase binding within the 5' non-template single strand rather than being part of the panhandle double-stranded structure in this region. The importance of a G residue at this position has been shown earlier in a single-step mutational analysis (Li and Palese, 1992), while non-template strand binding of RNA polymerase has been studied recently *in vitro* (Tiley et al., 1994). Different from the deleterious effect of an exchange at position 5 exchanges at positions 3 and in particular 8 are of minor importance. The series of 5' nucleotide exchanges has also been repeated for the pHL1102 version of the vRNA 3' end yielding exactly the same pattern of results, albeit at the somewhat reduced levels characteristic for pHL1102. The only result in both series not quite in agreement with a uniquely important role for a G-residue in position 5 is the triple exchange of pHL1126 which retains low promoter activity inspite of an A residue in that position. Due to altogether six concerted exchanges in positions 3, 5 and 8 as well as 3, 5 and 8 from the 5' and 3' end of the vRNA sequence the pHL1126 vRNA panhandle structure is indeed nearly equivalent to a wild-type cRNA panhandle, with the exception of an unpaired adenosine being present in position 10 of pHL1126 while an unpaired uridine at position 10 is part of the wild-type cRNA structure. This correlation may indicate a correct structure in pHL1126 for several other residues of (minor) importance which, therefore, apparently allows to compensate for the missing G residue in position 5, even if at a clearly reduced level of activity. - In the parallel pHL1102 series the corresponding triple exchange clone pHL1125 does not show any promoter activity; however, because of its deviation at position 5 it does not completely resemble the cRNA panhandle structure.

#### Mutational analysis of the panhandle bulge structure around nucleotide 10

An extra, unpaired residue in position 10 at the 5' end is a specific feature of the influenza viral RNA panhandle structure. It is causing or at least enforcing a major bulge of the structure, together with unpaired residues at position 9, and might be part of a specific recognition element of that structure by viral RNA polymerase. In order to investigate the importance of that particular structural feature, a further series of plasmid constructs has been initiated, again based on pHL1104 and its 3' terminal sequence as a reference. A perfectly matched RNA double-strand without any bulge has been achieved either by inserting an additional U residue in the 3' end sequence opposite A10 (pHL1140) or by deleting the A10 residue from the 5' sequence (pHL1152). Finally, a bulge of opposite direction was created in the panhandle structure of pHL1164 with an extra U residue in position 10 of the 3' end, and position 10 deleted from the 5' end sequence. While the latter two constructs proved inactive in the CAT assay, pHL1140 did show some promoter activity, albeit at a reduced level. We conclude from this result that a bulge in this region may not be recognized directly by viral RNA polymerase but may serve as a flexible joint between two more rigid structural elements that are involved in immediate contact with viral polymerase. The necessary RNA bending may also, but less efficiently be achieved in an A-U-basepaired structure like pHL1140, while the other two structures would not permit such type of interaction with RNA polymerase. This interpretation has also been substantiated in a further series of variations in this region.

#### Serial passaging of influenza virus carrying promoter mutants

All previous experiments consisted of a first measurement of viral mRNA synthesis in DNA-transfected and infected B82 cells, followed by a second measurement of viral mRNA synthesis in infected MDCK cells, after passaging of progeny virus containing supernatants. CAT expression in infected cells upon viral passaging requires packaging of pseudo-viral vRNAs, in addition to new rounds of viral mRNA synthesis in those cells leading to CAT expression again. All viral promoter mutants analysed and found active in transfected and helper-infected B82 cells also resulted in CAT expression after transfer, and consistently in equivalent ratios of activity. Packaging, therefore, cannot be correlated with any specific element in the vRNA promoter structure so far, and does not appear to be a limiting factor in constructing influenza virus mutants in this system. While CAT expression after passaging in general appeared to be increased over the levels before passaging this might have been simply the result of different cells being used for the first and second step of CAT analysis, with MDCK being superior to B82 cells in influenza mRNA synthesis and also in progeny yields. Therefore, several experiments of serial passage have been performed using pHL1104 derived influenza supernatants and others, in MDCK cells. In these serial passages, always done using aliquots of supernatants harvested eight hours after infection for further transfer, a stepwise increase of CAT expression is observed (Fig. 2). Apparently the superior performance of viral RNA promoters carrying sequence deviations according to pHL1104 is not only true for viral mRNA synthesis, but also for viral RNA replication, even if not to the same extent.

Therefore, mutant viral RNAs of this character become accumulated and effectively selected in further passaging, while packaging may be a neutral event in this regard, at least for the variants analysed here.

### Serial passaging extended

During further passaging of supernatants the CAT containing influenza segment carrying the mutationally altered viral promoter sequences became accumulated in a stepwise manner in the population of progeny viruses. In order to demonstrate this effect on the level of individual viruses being transferred we isolated in three independent experiments 50 to 85 plaques each after a third round of passage on MDCK cells. Each cell lysate obtained for the individual plaques was assayed for CAT activity according to the standard protocol. While in two of the experiments the fraction of CAT positive plaques was in the range of 4 to 8% (1 out of 50, 4 out of 40 plaques) in one of these series this fraction amounted to 47% (19 of 40 plaques). Both of these results demonstrate a substantial increase over the initial fraction of CAT-segment containing virus, which may be calculated to be in the range of  $10^{-5}$  or at most  $10^{-4}$ , and slight variations in the conditions of growth during three steps of transfer may precipitate to result in the observed differences of CAT positive plaques. While every CAT positive plaque demonstrates the amplification of nine (not eight) viral RNA segments present in the initially infected cell, this may have resulted from a single virus carrying nine or more RNA segments from coinfection by two defective viruses able to complement each other.

Necessarily, accumulation of a pseudo-viral segment not contributing to viral growth will, in further steps, become lethal to viral growth, even if a majority of virions may contain an average of eleven rather than eight RNA segments (Hsu et al. 1987). Packaging of viral RNA-segments based on a general packaging signal identical for all eight segments and realized via a specific interaction chain: vRNA panhandle structure - viral RNA polymerase - viral NP protein - viral M1 protein will reflect the pools of the various vRNA segments in infected cells, and therefore may be biased towards an RNA segment superior in replication and overrepresented in that pool. Biased replication and packaging will, however, lead to accumulation of lethal viral particles due to an imbalance between the eight (or nine) viral RNA segments. This prediction is borne out in continuing the viral passage of pHL1104 derived influenza supernatants beyond step three as exemplified in Fig. 2. While CAT expression based on transcription of the pHL1104 derived pseudoviral RNA segments is increased further up to the fifth passage the number of viable viruses reaches a maximum already after the second step of viral passaging, thus demonstrating the continuous accumulation of an over-replicated foreign segment, based on a superior panhandle sequence.

At a stage representing the third or fourth passage as displayed in Fig. 2 a virus preparation obtained in this way can be regarded as the equivalent of an attenuated viral strain. While the concentration of attenuated virus particles that can be achieved in this way may appear to be limited a stage equivalent to passage 4 in Fig. 2 may be delayed upon coinfection with wildtype helper virus during first or second steps of transfer, and considerably increased concentrations of attenuated virus preparations might be achievable in this way.

### DISCUSSION

In influenza viral RNA synthesis parental negative-strand vRNA is copied into plus-strand cRNA, which again is copied into progeny vRNA, from the first to the last nucleotide. This amplification of viral RNAs, however, proceeds in an inherently asymmetric way, since vRNA molecules are synthesized in excess over cRNA molecules. This result is consistent with the idea that cRNA carries a promoter structure more active in binding viral RNA polymerase and in initiation of RNA synthesis, i.e. 'stronger' than does vRNA. While at first simply the two 3' ends of single-stranded vRNA and cRNA templates have been implicated as promoter sequences, the detection of double-stranded panhandle structures involving both ends of the vRNA sequence in virions (Hsu et al., 1987) suggested more complicated substrates for RNA polymerase binding and initiation of daughter-strand synthesis. A slightly different panhandle structure has also been observed with model vRNA molecules in the absence of viral proteins *in vitro* (Baudin et al., 1994), possibly calling for a structural change upon viral RNA polymerase binding, i.e. a bulge may be shifted from position 4 to position 10 in that reaction (see Fig. 1). While originally several of the RNA polymerase / vRNA binding experiments *in vitro* appeared to show recognition only of 3' end oligonucleotides, this has since been shown to be an artifact after pure, recombinant viral polymerase free of residual RNA became available, instead of enzyme preparations from virions. Under these conditions RNA polymerase binding to viral RNA as well as endonucleolytic cleavage of cellular mRNAs by subunit PB2 was observed to depend on vRNA 5' plus 3' terminal sequence binding, with even higher affinity for the 5' non-template segment (Hagen et al., 1994; Tiley et al., 1994).

Different from the employment of both vRNA and cRNA promoter structures in replication physiologically only vRNA promoters will also serve in initiation of viral mRNA synthesis according to the cap-snatching mechanism (Plotch et al., 1979; Braam et al., 1983). While it has been claimed that cRNA promoters would not have the capacity to act according to this scheme (Tiley et al., 1994), the failure to observe viral antisense mRNA molecules may simply reflect the inavailability of cRNA molecules early in infection, i.e. in the absence of surplus viral NP protein, and small amounts of such molecules might even have gone undetected. In this invention we describe a mutagenizational analysis of the vRNA

promoter structure *in vivo* which in approaching the structure of the cRNA promoter via three nucleotide exchanges shows considerably improved activity in viral mRNA synthesis over vRNA promoter wild-type levels. Continuing increase of viral CAT mRNA expression during consecutive steps of viral passaging suggests that the same vRNA promoter mutants also show increased activity in cRNA synthesis, both in accordance with the idea that the cRNA promoter structure might be 'stronger' than the vRNA promoter, also in initiation of viral mRNA synthesis.

Additional variations of the 5' terminal sequence clearly indicate the major importance of a G residue in position 5, irrespective of complementarity or not to position 5 at the 3' end. The unique role of this G residue has been observed before in a serial mutagenizational analysis (Li and Palese, 1992). According to both data guanosine residue 5 may be involved in single-strand binding of RNA polymerase as has indeed been observed for the non-template strand terminal segment (Tiley et al., 1994). While panhandle double-strand structures are likely to constitute the initial RNA polymerase binding substrate a partial separation of template and non-template strands is expected to take place consecutively resulting in a 'forked structure' such as proposed by Fodor et al. (1994). Specific and tight binding of RNA polymerase in this structure may predominantly be oriented towards sequence elements in the non-template strand, since the growing point of RNA synthesis will have to move along the entire template strand following its initiation. It is, therefore, possible that such a binding interaction survives most or all of an individual round of mRNA synthesis as has been proposed (Tiley et al., 1994).

The triple nucleotide exchanges as introduced in vRNA molecules derived from pHL1104 templates will create three additional basepairs able to stabilize the panhandle structure in general, but more specifically they will favor a bulged adenosine 10 over the bulged adenosine 4 conformation as observed for the wild-type sequence *in vitro* (Baudin et al., 1994). Since the changes introduced here lead to a considerable enhancement of promoter activity we propose that a bulged 10 conformation may be the structure underlying the vRNA / polymerase binding reaction, which otherwise would have to be achieved only as a result of that interaction. A bulged 10 adenosine residue may constitute a kind of flexible joint or angular kink which in turn suggests two major, structurally stable binding sites to the left and right of this element. One of these sites has to be the double-stranded sequence element of (in average) six basepairs extending from positions 11 to 16 and 10 to 15, respectively. While the distal three basepairs are known to be variable for the various RNA segments, basepair 13/12 has been shown to be exchangeable experimentally, and also the number of basepairs has been reduced to four without complete loss of function (Luo et al., 1991). With all of these data it seems clear that the main recognition element in this region is an RNA double-strand of certain stability, while it remains possible that residue 12 guanosine and potentially others are also recognized individually within that structure. A major second binding element for RNA polymerase on the other side relative to position 10 is less evident, but may be located in a distance of nearly one helical turn in the de-bulged region around position 4, since direct contacts are suggested by that initial conformational interaction, and also by the specific requirement of a guanosine residue in position 5, which is likely to interact not only during, but also before partial strand separation in that region, i.e. in the panhandle as well as the forked structure. While an extra adenosine residue in position 10 may be optimal for creating a correctly shaped bulge in this region of RNA, structural variants are possible in this regard (see pHL 1140) which excludes direct interactions between RNA polymerase and residues constituting that bulge.

In summary we are proposing a model (see Fig. 1) of consecutive steps of interaction between a vRNA or cRNA promoter structure and viral RNA polymerase:

bulged 4 panhandle → bulged 10 panhandle / polymerase → forked RNA / polymerase (bound to 5G and ds element 11-16) → initiation of RNA synthesis (recognition of 3' end of template).

## MATERIALS AND METHODS

### Plasmid constructions

Plasmids with mutated vRNA and/or mutated cRNA promoter sequences are derivatives of pHL926 (Zobel et al., 1993; Neumann et al., 1994). In pHL926 a hybrid CAT cDNA with flanking non-coding sequences derived from influenza vRNA segments has been precisely inserted in antisense orientation between mouse rDNA promoter and terminator sequences. The CAT reporter gene in this way has been introduced by exactly replacing the coding sequence for hemagglutinin, retaining the untranslated viral 5' and 3' sequences of segment 4.

vRNA 5' end mutations were created by PCR, using a general primer hybridizing to a position in the flanking rDNA promoter sequence, and a specific primer carrying the desired nucleotide substitution to be introduced in the viral terminal sequence. The polymerase chain reaction products were first digested by the restriction enzymes *Bgl*II and *Spe*I, inserted into the left boundary position by exchanging the segment between these appropriate restriction sites in pHL926, and finally confirmed in their constitution by DNA Sanger sequencing.

Generation of vRNA 3' end mutations followed the same general scheme at the right boundary. PCR products were obtained by using a general primer complementary to a CAT gene internal sequence position, and a specific primer with appropriate nucleotide exchanges inserted into its sequence. Following digestion with restriction enzymes *Nco*I and

Scal, the PCR products were cloned into *Nco*I- and *Scal*(partially)-digested plasmid pHL926. Any PCR derived sequences were investigated by DNA sequencing.

For constructs with both 5' end and 3' end mutations in combination, 5' variation containing fragments were obtained by *Bgl*II and *Spe*I restriction and inserted into the appropriate 3' terminal variation plasmids.

## Cells and viruses

Influenza A/FPV/Bratislava viruses were grown in NIH3T3 cells. For transfection and passaging experiments B82 cells (a mouse L cell line) and MDCK cells were used.

## Lipofectamin DNA transfection and influenza virus helper infection

For DNA transfection 10<sup>7</sup> B82 cells were used. 5 µg of plasmid DNA were mixed with 60 µg of Lipofectamin (Lipofectamin™, GIBCO/BRL) in serum-free medium and incubated at room temperature for 10-15 min. This mixture was added to the cells washed twice with serum-free medium, and the incubation with Lipofectamin/DNA was continued for 1 hr. After further incubation with DMEM medium for 1 hr the transfected B82 cells were infected with influenza A/FPV/Bratislava at a multiplicity of infection of 0.01 to 1 for another 30-60 min. Further incubation was performed with DMEM medium.

## Passaging of virus containing supernatants

Under standard conditions 8 hr after influenza infection (at moi 0.1 to 1) cells were harvested for CAT assays, and supernatants were collected and spun down at 1200 rpm for 5 min for removal of cell debris.

Aliquots of virus containing cleared supernatants were used for plaque tests, and another aliquot was adsorbed to 10<sup>7</sup> MDCK cells for 30-60 min for further passaging. Again 8 hr after infection the CPE was verified, and cells and supernatants were collected and treated as before.

## CAT assay

Cell extracts were prepared as described by Gorman et al. (1982). CAT assays were done with [<sup>14</sup>C]chloramphenicol or fluorescent-labeled chloramphenicol (borondipyrromethane difluoride fluorophore; FLASH CAT Kit, Stratagene) as substrates.

For [<sup>14</sup>C]chloramphenicol the assay mixture contained: 0.1 µCi [<sup>14</sup>C]chloramphenicol, 20 µl 4 mM Acetyl-CoA, 25 µl 1 M Tris-HCl (pH 7.5) and 50 µl of cell lysate in a total volume of 150 µl. The assay mixture for the fluorescent-labeled substrate contained (in a final volume of 80 µl): 10 µl 0.25 M Tris-HCl (pH 7.5), 10 µl 4 M Acetyl-CoA, 10 µl fluorescent-labeled chloramphenicol, and 50 µl of cell lysate. After an incubation time of 16 hr the reaction products were separated by chromatography and either autoradiographed or visualized by UV illumination and photography.

## REFERENCES

- Baudin, F., Bach, C., Cusack, S. and Ruigrok, R.W.H. (1994) *The EMBO J.*, **13**, 3158-3165.
- Braam, J., Uhmanen, I. and Krug, R. (1983) *Cell*, **34**, 609-618.
- Compans, R.W., Content, J. and Duesberg, P.H. (1972) *J. Virol.*, **10**, 795-800.
- Fodor, E., Seong, B.L. and Brownlee, G.G. (1993) *J. Gen. Virol.*, **74**, 1327-1333.
- Fodor, E., Pritlove, D.C. and Brownlee, G.G. (1994) *J. Virol.*, **68**, 4092-4096.
- Gorman, M., Moffat, L. and Howard, B. (1982) *Mol. Cell Biol.*, **2**, 1044-1057.
- Hagen, M., Chung, T.D.Y., Butcher, J.A. and Krystal, M. (1994) *J. Virol.*, **68**, 1509-1515.
- Honda, A., Ueda, K., Nagata, K. and Ishihama, A. (1987) *J. Biochem.*, **102**, 1241-1249.
- Hsu, M., Parvin, J.D., Gupta, S., Krystal, M. and Palese, P. (1987) *Proc. Natl. Acad. Sci. USA*, **84**, 8140-8144.
- Li, X. and Palese, P. (1992) *J. Virol.*, **66**, 4331-4338.
- Luo, G., Luytjes, W., Enami, M. and Palese, P. (1991) *J. Virol.*, **65**, 2861-2867.
- Martin, J., Albo, C., Ortin, J., Melero, J.A. and Portela, A. (1992) *J. Gen. Virol.*, **73**, 1855-1859.
- Neumann, G., Zobel, A. and Hobom, G. (1994) *Virology*, **202**, 477-479.
- Plotch, S., Bouloy, M. and Krug, R.M. (1979) *Proc. Natl. Acad. Sci. USA*, **76**, 1618-1622.
- Seong, B.L. and Brownlee, G.G. (1992) *J. Virol.*, **73**, 3115-3124.
- Shapiro, G. and Krug, R. (1988) *J. Virol.*, **62**, 2285-2290.
- Tiley, L.S., Hagen, M., Matthews, J.T. and Krystal, M. (1994) *J. Virol.*, **68**, 5108-5116.
- Yamanaka, K., Ogasawara, N., Yoshikawa, H., Ishihama, A. and Nagata, K. (1991) *Proc. Natl. Acad. Sci. USA*, **88**: 5369-

5373.

Zobel, A., Neumann, G. and Hobom, G. (1993) *Nucl. Acids Res.*, **21**, 3607-3614.

## LEGENDS TO FIGURES

**Fig. 1.** Proposed scheme of consecutive conformational steps occurring prior to initiation of viral mRNA synthesis in influenza vRNA, in wildtype and pHL1104 derived mutant sequences. Positions of triple mutation in pHL1104 vRNA are indicated in bold and larger size letters.

(A) Free RNA panhandle structure, bulged at position 4 (wildtype vRNA; Baudin et al, 1994) or at position 10 (mutant vRNA). (B) Bulged 10 panhandle structures after binding of viral RNA polymerase; proposed protein binding positions marked by underlinements. (C) Forked structures of partial strand separation. (D) Initiation of viral mRNA synthesis via hybridization of capped primer oligonucleotide.

**Fig. 2.** Serial passaging of pHL 1104-derived progeny viruses.

10<sup>7</sup> B82 cells were transfected with 5 µ of pHL 1104 DNA (in 60 µg Lipofectamin) and infected two hours later with influenza A/FPV/Bratislava (m.o.i.:1). 8 hr post-infection the cells were assayed for plaque forming units (dark column) and for CAT activity (hatched column) After sedimentation an other aliquot of the supernatant was adsorbed to 10<sup>7</sup> MDCK cells. Further rounds of passaging were done equivalently by harvesting the cells 8 hr after infection for assaying CAT activities, whereas an aliquot of the supernatant was always adsorbed to fresh MDCK cells. Numbers of serial passages are indicated at the bottom. Plaque forming units per ml refer to the left ordinate, CAT expression rates (relative



to primary infection levels) to the ordinate on the right.

SEQUENCE LISTING

5

10

(1) GENERAL INFORMATION:

15

(i) APPLICANT:

(A) NAME: Bayer AG

(B) STREET: Bayerwerk

20

(C) CITY: Leverkusen

(E) COUNTRY: Deutschland

25

(F) POSTAL CODE (ZIP): 51368

(G) TELEPHONE: (0)214-3061455

30

(H) TELEFAX: (0)214-303482

35

(ii) TITLE OF INVENTION: Vaccination virus, method of making it and  
pharmaceutical composition comprising that virus

40

(iii) NUMBER OF SEQUENCES: 5

45

(iv) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk

(B) COMPUTER: IBM PC compatible

50

(C) OPERATING SYSTEM: PC-DOS/MS-DOS

(D) SOFTWARE: PatentIn Release #1.0, Version #1.30B (EPO)

55

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5241 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Influenza virus, RNA sequence

(C) INDIVIDUAL ISOLATE: pHL926

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CTGGCGGCAG TAGCGCGGTG GTCCACCTG ACCCATGCC  
GAACTCAGAA GTGAAACGCC 60

5 GTAGCGCCGA TGGTAGTGTG GGGTCTCCCC ATGCGAGAGT  
AGGGAAGTGC CAGGCATCAA 120

10 ATAAAACGAA AGGCTCAGTC GAAAGACTGG GCCTTTCGTT  
TTATCTGTTG TTTGTCGGTG 180

15 AACGCTCTCC TGAGTAGGAC AAATCCGCCG GGAGCGGATT  
TGAACGTTGC GAAGCAACGG 240

20 CCCGGAGGGT GGCGGGCAGG ACGCCCGCCA TAAACTGCCA  
GGCATCAAAT TAAGCAGAAG 300

25 GCCATCCTGA CGGATGGCCT TTTTGCGTTT CTACAAACTC  
TTTTGTTTAT TTTTCTAAAT 360

30 ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA  
TAAATGCTTC AATAATATTG 420

35 AAAAAGGAAG AGTATGAGTA TTCAACATTT CCGTGTCGCC  
CTTATTCCT TTTTTCGGC 480

40 ATTTTGCCTT CCTGTTTTTG CTCACCCAGA AACGCTGGTG  
AAAGTAAAAG ATGCTGAAGA 540

45 TCAGTTGGGT GCACGAGTGG GTTACATCGA ACTGGATCTC  
AACAGCGGTA AGATCCTTGA 600

50

55

5 GAGTTTTTCGC CCCGAAGAAC GTTTTCCAAT GATGAGCACT  
TTTAAAGTTC TGCTATGTGG 660

10 CGCGGTATTA TCCCGTGTTG ACGCCGGGCA AGAGCAACTC  
GGTCGCCGCA TACTATTTC 720

15 TCAGAATGAC TTGGTTGAGT ACTCACCAGT CACAGAAAAG  
CATCTTACGG ATGGCATGAC 780

20 AGTAAGAGAA TTATGCAGTG CTGCCATAAC CATGAGTGAT  
AACACTGCCG CCAACTTACT 840

25 TCTGACAACG ATCGGAGGAC CGAAGGAGCT AACCGCTTTT  
TTGCACAACA TGGGGGATCA 900

30 TGTAACCTCGC CTTGATCGTT GGGAACCGGA GCTGAATGAA  
GCCATACCAA ACGACGAGCG 960

35 TGACACCACG ATGCCTGCAG CAATGGCAAC AACGTTGCGC  
AAACTATTAA CTGGCGAACT 1020

40 ACTTACTCTA GCTTCCCGGC AACAATTAAT AGACTGGATG  
GAGGCGGATA AAGTTGCAGG 1080

45 ACCACTTCTG CGCTCGGCCC TTCCGGCTGG CTGGTTTATT  
GCTGATAAAT CTGGAGCCGG 1140

50

55

5 TGAGCGTGGG TCTCGCGGTA TCATTGCAGC ACTGGGGCCA  
GATGGTAAGC CCTCCCGTAT 1200

10 CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT  
GAACGAAATA GACAGATCGC 1260

15 TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAAGTGTCA  
GACCAAGTTT ACTCATATAT 1320

20 ACTTTAGATT GATTTAAAAC TTCATTTTTA ATTTAAAAGG  
ATCTAGGTGA AGATCCTTTT 1380

25 TGATAATCTC ATGACCAAAA TCCCTTAACG TGAGTTTTTCG  
TTCCACTGAG CGTCAGACCC 1440

30 CGTAGAAAAG ATCAAAGGAT CTTCTTGAGA TCCTTTTTTTT  
CTGCGCGTAA TCTGCTGCTT 1500

35 GCAAACAAAA AAACCACCGC TACCAGCGGT GGTTTGTTTG  
CCGGATCAAG AGCTACCAAC 1560

40 TCTTTTTCCG AAGGTAAGT GCTTCAGCAG AGCGCAGATA  
CCAAATACTG TCCTTCTAGT 1620

45 GTAGCCGTAG TTAGGCCACC ACTTCAAGAA CTCTGTAGCA  
CCGCCTACAT ACCTCGCTCT 1680

50

55

5 GCTAATCCTG TTACCAGTGG CTGCTGCCAG TGGCGATAAG  
TCGTGTCTTA CCGGGTTGGA 1740

10 CTCAAGACGA TAGTTACCGG ATAAGGCGCA GCGGTCGGGC  
TGAACGGGGG GTTCGTGCAC 1800

15 ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA  
TACCTACAGC GTGAGCATTG 1860

20 AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GCGGGACAGG  
TATCCGGTAA GCGGCAGGGT 1920

25 CGGAACAGGA GAGCGCACGA GGGAGCTTCC AGGGGGAAAC  
GCCTGGTATC TTTATAGTCC 1980

30 TGTCGGGTTT CGCCACCTCT GACTTGAGCG TCGATTTTTG  
TGATGCTCGT CAGGGGGGCG 2040

35 GAGCCTATGG AAAAACGCCA GCAACGCGGC CCGAGATGCG  
CCGCGTGCGG CTGCTGGAGA 2100

40 TGGCGGACGC GATGGATATG TTCTGCCAAG GGTTGGTTTG  
CGCATTCACA GTTCTCCGCA 2160

45 AGAATTGATT GGCTCCAATT CTTGGAGTGG TGAATCCGTT  
AGCGAGGTGC CGCCGGCTTC 2220

5 CATTTCAGGTC GAGGTGGCCC GGCTCCATGC ACCGCGACGC  
AACGCGGGGA GGCAGACAAG 2280

10 GTATAGGGCG GCGCCTACAA TCCATGCCAA CCCGTTCCAT  
GTGCTCGCCG AGGCGGCATA 2340

15 AATCGCCGTG ACGATCAGCG GTCCAGTGAT CGAAGTTAGG  
CTGGTAAGAG CCGCGAGCGA 2400

20 TCCTTGAAGC TGTCCCTGAT GGTCGTCATC TACCTGCCTG  
GACAGCATGG CCTGCAACGC 2460

25

30 GGGCATCCCG ATGCCGCCGG AAGCGAGAAG AATCATAATG  
GGGAAGGCCA TCCAGCCTCG 2520

35 CGTCGCGAAC GCCAGCAAGA CGTAGCCCAG CGCGTCGGCC  
AGCTTGCAAT TCGCGCTAAC 2580

40 TTACATTAAT TGC GTTGCGC TCACTGCCCG CTTTCCAGTC  
GGGAAACCTG TCGTGCCAGC 2640

45 TGCATTAATG AATCGGCCAA CGCGCGGGGA GAGGCGGTTT  
GCGTATTGGG CGCCAGGGTG 2700

50 GTTTTTCTTT TCACCAGTGA GACGGGCAAC AGCTGATTGC  
CCTTCACCGC CTGGCCCTGA 2760

55

5 GAGAGTTGCA GCAAGCGGTC CACGCTGGTT TGCCCCAGCA  
GGCGAAAATC CTGTTTGATG 2820

10 GTGGTTGACG GCGGGATATA ACATGAGCTG TCTTCGGTAT  
CGTCGTATCC CACTACCGAG 2880

15 ATATCCGCAC CAACGCGCAG CCCGGACTCG GTAATGGCGC  
GCATTGCGCC CAGCGCCATC 2940

20 TGATCGTTGG CAACCAGCAT CGCAGTGGGA ACGATGCCCT  
CATTAGCAT TTGCATGGTT 3000

25 TGTGAAAAC CGGACATGGC ACTCCAGTCG CCTTCCCGTT  
CCGCTATCGG CTGAATTGA 3060

30 TTGCGAGTGA GATATTTATG CCAGCCAGCC AGACGCAGAC  
GCGCCGAGAC AGAACTTAAT 3120

35 GGGCCCCCGG TGACAGGGAC AGAGAGGGCT TCTGGAGGAA  
AAAAGAAAAA AAAAAAAAAA 3180

40 GATCCAAAGC TCCAGGGCGA GCTCGAATTC CCCGGTAAAG  
CCGCTTAAGA CATTCCCGCT 3240

45 CTTACACATC CCAGCCCTGA AAAAGGGCAT CAAAATAAAC  
CACACCTATG GTGTATGCAT 3300

50

55



5 TTACGTTGAC ACCATCGAAT GGTGCAAAAC CTTTCGCGGT  
ATGGCATGAT AGCGCCCGGA 3360

10 AGAGAGTCAA TTCAGGGTGG TGAATGTGAA ACCAGTAACG  
TTATACGATG TCGCAGAGTA 3420

15 TGCCGGTGTC TCTTATCAGA CCGTTTCCCG CGTGGTGAAC  
CAGGCCAGCC ACGTTTCTGC 3480

20 GAAAACGCGG GAAAAAGTGG AAGCGGCGAT GGC GGAGCTG  
AATTACATTC CCAACCGCGT 3540

25 GGCACAACAA CTGGCGGGCA AACAGTCGTT GCTGATTGGC  
GTTGCCACCT CCAGTCTGGC 3600

30 CCTGCACGCG CCGTCGCAAA TTGTCGCGGC GATTAAATCT  
CGCGCCGATC AACTGGGTGC 3660

35 CAGCGTGGTG GTGTCGATGG TAGAACGAAG CGGCGTCGAA  
GCCTGTAAAG CGGCGGTGCA 3720

40 CAATCTTCTC GCGCAACGCG TTCAGTGGGC TAGATCTACC  
GCGGTAGATC ATTA ACTATC 3780

45 CGCTGGATGA CCAGGATGCC ATTGCTGTGG AAGCTGCCTG  
CACTAATGTT CCGGCGTTAT 3840

5 TTCTTGATGT CTCTGACCAG ACACCCATCA ACAGTATTAT  
TTTCTCCCAT GAAGACGGTA 3900

10 CGCGACTGGG CGTGGAGCAT CTGGTCGCAT TGGGTCACCA  
GCAAATCGCG CTGTTAGCGG 3960

15 GCCCTGTACG TCTGAGGCCG AGGGAAAGCT ATGGGCGCGG  
TTTTCTTTCA TTGACCTGTC 4020

20 GGTCTTATCA GTTCTCCGGG TTGTCAGGTC GACCAGTTGT  
TCCTTTGAGG TCCGGTTCTT 4080

25 TTCGTTATGG GGTCATTTTT GGGCCACCTC CCCAGGTATG  
30 ACTTCCAGGT ATTCTCTGTG 4140

35 GCCTGTCACT TTCTCCCTG TCTCTTTTAT GCTTGTGATC TTTTAGATCT  
GGTCCTATTG 4200

40 GACCTGGAGA TAGGTAGTAG AAACAAGGGT GTTTTTAAAT  
ACTAGTACAT TACGCCCCGC 4260

45 CCTGCCACTC ATCGCAGTAC TGTTGTAATT CATTAAAGCAT  
TCTGCCGACA TGGAAGCCAT 4320

50 CACAGACGGC ATGATGAACC TGAATCGCCA GCGGCATCAG  
55 CACCTTGTCG CCTTGCGTAT 4380

5 AATATTTGCC CATGGTGAAA ACGGGGGCGA AGAAGTTGTC  
CATATTGGCC ACGTTTAAAT 4440

10 CAAAACTGGT GAAACTCACC CAGGGATTGG CTGAGACGAA  
AAACATATTC TCAATAAACC 4500

15 CTTTAGGGAA ATAGGCCAGG TTTTCACCGT AACACGCCAC  
ATCTTGCGAA TATATGTGTA 4560

20 GAAACTGCCG GAAATCGTCG TGGTATTCAC TCCAGAGCGA  
TGAAAACGTT TCAGTTTGCT 4620

25 CATGGAAAAC GGTGTAACAA GGGTGAACAC TATCCCATAT  
CACCAGCTCA CCGTCTTTCA 4680

30 TTGCCATACG GAATTCCGGA TGAGCATTCA TCAGGCGGGC  
AAGAATGTGA ATAAAGGCCG 4740

35 GATAAACTT GTGCTTATTT TTCTTTACGG TCTTTAAAAA  
GGCCGTAATA TCCAGCTGAA 4800

40 CGGTCTGGTT ATAGGTACAT TGAGCAACTG ACTGAAATGC  
CTCAAAATGT TCTTTACGAT 4860

45 GCCATTGGGA TATATCAACG GTGGTATATC CAGTGATTTT  
TTTCTCCATG ATTAATAGAA 4920

55

TTATCCCCTG TTTCTACTCC CCCCCAACTT CGGAGGTCGA  
CCAGTACTCC GGGCGAAACT 4980

TTGTTTTTTT TTTTCCCCC GATGCTGGAG GTCGACCAGA  
TGTCCGAAAG TGTCCCCCCC 5040

CCCCCCCCC CCCGGCGCGG AACGGCGGGG CCACTCTGGA  
CTCTTTTTT TTTTTTTTT 5100

TTTTTTTTTG GGGATCCTCT AGAGTCGACC TGCAGCCCAA  
GCTAGCGGCC GCTAGCTTCT 5160

GTTTTGGCGG ATGAGAGAAG ATTTTCAGCC TGATACAGAT  
TAAATCAGAA CGCAGAAGCG 5220

GTCTGATAAA ACAGAATTG C 5241

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 5241 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Influenza virus, RNA sequence

(C) INDIVIDUAL ISOLATE: pHL1104

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CTGGCGGCAG TAGCGCGGTG GTCCACCTG ACCCATGCC  
GAACTCAGAA GTGAAACGCC 60

GTAGCGCCGA TGGTAGTGTG GGGTCTCCCC ATGCGAGAGT  
AGGGAAGTGC CAGGCATCAA 120

ATAAAACGAA AGGCTCAGTC GAAAGACTGG GCCTTTCGTT  
TTATCTGTTG TTTGTCGGTG 180

AACGCTCTCC TGAGTAGGAC AAATCCGCCG GGAGCGGATT  
TGAACGTTGC GAAGCAACGG 240

CCCGGAGGGT GCGGGGCAGG ACGCCCGCCA TAAACTGCCA  
GGCATCAAAT TAAGCAGAAG 300

5 GCCATCCTGA CGGATGGCCT TTTTGC GTTT CTACAAACTC  
TTTTGTTTAT TTTTCTAAAT 360

10 ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA  
TAAATGCTTC AATAATATTG 420

15 AAAAAGGAAG AGTATGAGTA TTCAACATTT CCGTGTCGCC  
CTTATTCCT TTTTTCGGC 480

20 ATTTTGCCTT CCTGTTTTTG CTCACCCAGA AACGCTGGTG  
AAAGTAAAAG ATGCTGAAGA 540

25 TCAGTTGGGT GCACGAGTGG GTTACATCGA ACTGGATCTC  
AACAGCGGTA AGATCCTTGA 600

30 GAGTTTTTCGC CCCGAAGAAC GTTTTCCAAT GATGAGCACT  
TTTAAAGTTC TGCTATGTGG 660

35 CGCGGTATTA TCCCGTGTTG ACGCCGGGCA AGAGCAACTC  
GGTCGCCGCA TAACTATTC 720

40 TCAGAATGAC TTGGTTGAGT ACTCACCAGT CACAGAAAAG  
CATCTTACGG ATGGCATGAC 780

45 AGTAAGAGAA TTATGCAGTG CTGCCATAAC CATGAGTGAT  
AACACTGCGG CCAACTTACT 840

5 TCTGACAACG ATCGGAGGAC CGAAGGAGCT AACCGCTTTT  
TTGCACAACA TGGGGGATCA 900

10 TGTAACCTCGC CTTGATCGTT GGAACCGGA GCTGAATGAA  
GCCATACCAA ACGACGAGCG 960

15 TGACACCACG ATGCCTTCAG CAATGGCAAC AACGTTGCGC  
AAACTATTAA CTGGCGAACT 1020

20 ACTTACTCTA GCTTCCCGGC AACAATTAAT AGACTGGATG  
GAGGCGGATA AAGTTGCAGG 1080

25 ACCACTTCTG CGCTCGGCCC TTCCGGCTGG CTGGTTTATT  
GCTGATAAAT CTGGAGCCGG 1140

30 TGAGCGTGGG TCTCGCGGTA TCATTGCAGC ACTGGGGCCA  
GATGGTAAGC CCTCCCGTAT 1200

35 CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT  
GAACGAAATA GACAGATCGC 1260

40 TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAACGTGCA  
GACCAAGTTT ACTCATATAT 1320

45 ACTTTAGATT GATTTAAAC TTCATTTTTA ATTTAAAAGG  
ATCTAGGTGA AGATCCTTTT 1380

50

55

5 TGATAATCTC ATGACCAAAA TCCCTTAACG TGAGTTTTTCG  
TTCCACTGAG CGTCAGACCC 1440

10 CGTAGAAAAG ATCAAAGGAT CTTCTTGAGA TCCTTTTTTTT  
CTGCGCGTAA TCTGCTGCTT 1500

15 GCAAACAAAA AAACCACCGC TACCAGCGGT GGTTTGTTTG  
CCGGATCAAG AGCTACCAAC 1560

20 TCTTTTTCCG AAGGTAAGTG GCTTCAGCAG AGCGCAGATA  
CCAAATACTG TCCTTCTAGT 1620

25 GTAGCCGTAG TTAGGCCACC ACTTCAAGAA CTCTGTAGCA  
CCGCCTACAT ACCTCGCTCT 1680

30 GCTAATCCTG TTACCAGTGG CTGCTGCCAG TGGCGATAAG  
TCGTGTCTTA CCGGGTTGGA 1740

35 CTCAAGACGA TAGTTACCGG ATAAGGCGCA GCGGTCGGGC  
TGAACGGGGG GTTCGTGCAC 1800

40 ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA  
TACCTACAGC GTGAGCATTG 1860

45 AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG  
TATCCGGTAA GCGGCAGGGT 1920



CGGAACAGGA GAGCGCACGA GGGAGCTTCC AGGGGGAAAC  
GCCTGGTATC TTTATAGTCC 1980

TGTCGGGTTT CGCCACCTCT GACTTGAGCG TCGATTTTGT  
TGATGCTCGT CAGGGGGGCG 2040

GAGCCTATGG AAAAACGCCA GCAACGCGGC CCGAGATGCG  
CCGCGTGCGG CTGCTGGAGA 2100

TGGCGGACGC GATGGATATG TTCTGCCAAG GGTGTTTGT  
CGCATTCACA GTTCTCCGCA 2160

AGAATTGATT GGCTCCAATT CTTGGAGTGG TGAATCCGTT  
AGCGAGGTGC CGCCGGCTTC 2220

CATTCAGGTC GAGGTGGCCC GGCTCCATGC ACCGCGACGC  
AACGCGGGGA GGCAGACAAG 2280

GTATAGGGCG GCGCCTACAA TCCATGCCAA CCCGTTCCAT  
GTGCTCGCCG AGGCGGCATA 2340

AATCGCCGTG ACGATCAGCG GTCCAGTGAT CGAAGTTAGG  
CTGGTAAGAG CCGCGAGCGA 2400

TCCTTGAAGC TGTCCCTGAT GGTCGTCATC TACCTGCCTG  
GACAGCATGG CCTGCAACGC 2460

5 GGGCATCCCG ATGCCGCCGG AAGCGAGAAG AATCATAATG  
GGGAAGGCCA TCCAGCCTCG 2520

10 CGTCGCGAAC GCCAGCAAGA CGTAGCCCAG CGCGTCGGCC  
AGCTTGCAAT TCGCGCTAAC 2580

15 TTACATTAAT TGC GTTGCGC TCACTGCCCCG CTTTCCAGTC  
GGGAAACCTG TCGTGCCAGC 2640

20 TGCATTAATG AATCGGCCAA CGCGCGGGGA GAGGCGGTTT  
GCGTATTGGG CGCCAGGGTG 2700

25 GTTTTTCTTT TCACCAGTGA GACGGGCAAC AGCTGATTGC  
CCTTCACCGC CTGGCCCTGA 2760

30 GAGAGTTGCA GCAAGCGGTC CACGCTGGTT TGCCCCAGCA  
GGCGAAAATC CTGTTTGATG 2820

35 GTGGTTGACG GCGGGATATA ACATGAGCTG TCTTCGGTAT  
CGTCGTATCC CACTACCGAG 2880

40 ATATCCGCAC CAACGCGCAG CCCGGACTCG GTAATGGCGC  
GCATTGCGCC CAGCGCCATC 2940

45 TGATCGTTGG CAACCAGCAT CGCAGTGGA ACGATGCCCT  
CATTGAGCAT TTGCATGGTT 3000

TGTTGAAAAC CGGACATGGC ACTCCAGTCG CCTTCCCGTT  
 5 CCGCTATCGG CTGAATTTGA 3060

TTGCGAGTGA GATATTTATG CCAGCCAGCC AGACGCAGAC  
 10 GCGCCGAGAC AGAACTTAAT 3120

GGGCCCCCGG TGACAGGGAC AGAGAGGGCT TCTGGAGGAA  
 15 AAAAGAAAAA AAAAAAAAAA 3180

GATCCAAAGC TCCAGGGCGA GCTCGAATTC CCCGGTAAAG  
 20 CCGCTTAAGA CATTCCCGCT 3240

CTTACACATC CCAGCCCTGA AAAAGGGCAT CAAAATAAAC  
 25 CACACCTATG GTGTATGCAT 3300

TTACGTTGAC ACCATCGAAT GGTGCAAAAC CTTTCGCGGT  
 30 ATGGCATGAT AGCGCCCGGA 3360

AGAGAGTCAA TTCAGGGTGG TGAATGTGAA ACCAGTAACG  
 40 TTATACGATG TCGCAGAGTA 3420

TGCCGGTGTC TCTTATCAGA CCGTTTCCCG CGTGGTGAAC  
 45 CAGGCCAGCC ACGTTTCTGC 3480

GAAAACGCGG GAAAAAGTGG AAGCGGCGAT GGCGGAGCTG  
 50 AATTACATTC CCAACCGCGT 3540

5 GGCACAACAA CTGGCGGGCA AACAGTCGTT GCTGATTGGC  
GTTGCCACCT CCAGTCTGGC 3600

10 CCTGCACGCG CCGTCGCAAA TTGTCGCGGC GATTAAATCT  
CGCGCCGATC AACTGGGTGC 3660

15 CAGCGTGGTG GTGTCGATGG TAGAACGAAG CGGCGTCGAA  
GCCTGTAAAG CGGCGGTGCA 3720

20 CAATCTTCTC GCGCAACGCG TTCAGTGGGC TAGATCTACC  
GCGGTAGATC ATTAACATC 3780

25 CGCTGGATGA CCAGGATGCC ATTGCTGTGG AAGCTGCCTG  
CACTAATGTT CCGGCGTTAT 3840

30 TTCTTGATGT CTCTGACCAG ACACCCATCA ACAGTATTAT  
TTTCTCCCAT GAAGACGGTA 3900

35 CGCGACTGGG CGTGGAGCAT CTGGTCGCAT TGGGTCACCA  
GCAAATCGCG CTGTTAGCGG 3960

40 GCCCTGTACG TCTGAGGCCG AGGGAAAGCT ATGGGCGCGG  
TTTCTTTCA TTGACCTGTC 4020

45 GGTCTTATCA GTTCTCCGGG TTGTCAGGTC GACCAGTTGT  
TCCTTTGAGG TCCGGTTCTT 4080

50

55

5 TTCGTTATGG GGTCAATTTT GGGCCACCTC CCCAGGTATG  
ACTTCCAGGT ATTCTCTGTG 4140

10 GCCTGTCACT TTCCTCCCTG TCTCTTTTAT GCTTGTGATC TTTTAGATCT  
GGTCCTATTG 4200

15 GACCTGGAGA TAGGTAGTAG AAACAAGGGT GTTTTTAAAT  
ACTAGTACAT TACGCCCCGC 4260

20 CCTGCCACTC ATCGCAGTAC TGTTGTAATT CATTAAGCAT  
TCTGCCGACA TGGAAGCCAT 4320

25 CACAGACGGC ATGATGAACC TGAATCGCCA GCGGCATCAG  
CACCTTGTCG CCTTGCGTAT 4380

30 AATATTTGCC CATGGTGAAA ACGGGGGCGA AGAAGTTGTC  
CATATTGGCC ACGTTTAAAT 4440

35 CAAAACTGGT GAAACTCACC CAGGGATTGG CTGAGACGAA  
AAACATATTC TCAATAAACC 4500

40 CTTTAGGGAA ATAGGCCAGG TTTTCACCGT AACACGCCAC  
ATCTTGCGAA TATATGTGTA 4560

45 GAAACTGCCG GAAATCGTCG TGGTATTCAC TCCAGAGCGA  
TGAAAACGTT TCAGTTTGCT 4620

5 CATGGAAAAC GGTGTAACAA GGGTGAACAC TATCCCATAT  
CACCAGCTCA CCGTCTTTCA 4680

10 TTGCCATACG GAATTCCGGA TGAGCATTCA TCAGGCGGGC  
AAGAATGTGA ATAAAGGCCG 4740

15 GATAAAACTT GTGCTTATTT TTCTTTACGG TCTTTAAAAA  
GGCCGTAATA TCCAGCTGAA 4800

20 CGGTCTGGTT ATAGGTACAT TGAGCAACTG ACTGAAATGC  
CTCAAATGT TCTTTACGAT 4860

25 GCCATTGGGA TATATCAACG GTGGTATATC CAGTGATTTT  
TTTCTCCATG ATTAATAGAA 4920

30 TTATCCCCTG TTTCTACTCC CCCCCAACTT CGGAGGTCGA  
35 CCAGTACTCC GGGCGAAACT 4980

40 TTGTTTTTTT TTTTCCCCC GATGCTGGAG GTCGACCAGA  
TGTCGAAAG TGTCCCCCCC 5040

45 CCCCCCCCCC CCCGGCGCGG AACGGCGGGG CCACTCTGGA  
CTCTTTTTTT TTTTTTTTTT 5100

50 TTTTTTTTTG GGGATCCTCT AGAGTCGACC TGCAGCCCAA  
GCTAGCGGCC GCTAGCTTCT 5160

55

5 GTTTTGGCGG ATGAGAGAAG ATTTTCAGCC TGATACAGAT  
TAAATCAGAA CGCAGAAGCG 5220

10 GTCTGATAAA ACAGAATTTG C 5241

15 (2) INFORMATION FOR SEQ ID NO: 3:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 base pairs

25 (B) TYPE: nucleic acid

(C) STRANDEDNESS: single

30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

35 (iii) HYPOTHETICAL: NO

40 (iv) ANTI-SENSE: NO

45 (vi) ORIGINAL SOURCE:

50 (A) ORGANISM: Influenza virus, 3' RNA sequence

(C) INDIVIDUAL ISOLATE: Wild Type vRNA Promotor Element

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

UCGUUUUCGU CCC

13

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 13 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Influenza virus, vRNA 5' sequence

(C) INDIVIDUAL ISOLATE: pHL1104 vRNA Promoter Element

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:



UCAUCUUUGU CCC

13

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 14 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: RNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Influenza virus, cRNA 3' sequence

(C) INDIVIDUAL ISOLATE: cRNA Promoter element

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

AGUAGAAACA AGGG

14

Claims

1. A segmented RNA virus characterized in that it comprises one or more segments which have been genetically modified to show improved transcription, replication and/or expression rates.
2. The virus of claim 1, wherein one or more modifications have been introduced in the noncoding region(s) and/or in the coding region(s).
3. The virus of any of claims 1 or 2, wherein at least one modified segment is derived from an original one by sequence variation(s).
4. The virus of any of claims 1 or 2, wherein at least one modified segment is an artificial addition to the set of original segments.
5. The virus of claim 4, wherein the modified segment comprises a nucleotide sequence which codes for a protein or peptide which is foreign to the original virus.
6. The virus of claim 5, wherein the foreign protein or peptide constitutes an antigen or antigen-like sequence, a T-cell epitope or related sequence.
7. The virus of any of claims 5 or 6, wherein the segment comprises repetitions of an antigen or epitope or other peptide or protein..
8. The virus of any of claims 7 to 9, wherein the antigen or epitope is derived from HIV, Herpes-Virus, Rhinovirus or CMV.
9. A pharmaceutical preparation of a vaccine comprising the virus of any of claims 1 to 8.
10. Use of the virus of any of claims 1 to 8 for the preparation of pharmaceuticals.

Fig. 1





Fig. 2





European Patent  
Office

## EUROPEAN SEARCH REPORT

Application Number  
EP 94 11 5505

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	CARRASCO, L. et al. 'Regulation of gene expression in animal viruses'; 1993, PLENUM PRESS, NEW YORK pages 107-114, GARCIA-SASTRE, A. & PALESE, P. : 'Infectious influenza viruses from cDNA-derived RNA: reverse genetics' * page 109, line 10 - line 11 * * page 112, line 17 - page 113 * ---	1-10	C12N15/86 C12N7/00 C12N15/62 A61K39/145 A61K35/76
Y	J GEN VIROL 73 (12). 3115-3124, 1992 SEONG, B. ET AL. 'NUCLEOTIDES 9 TO 11 OF THE INFLUENZA A VIRION RNA PROMOTER ARE CRUCIAL FOR ACTIVITY IN-VITRO.' * page 3117, left column, line 14 - right column, line 2 * * page 3119, paragraph 2 - page 3120 * * table 4 * * page 3123, right column, line 8 - page 3123 * ---	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.6)  C12N A61K
Y	CELL, vol. 59, no.6, 22 December 1989 CAMBRIDGE, MA US, pages 1107-1113, LUYTJES, W. ET AL. 'Amplification, expression, and packaging of a foreign gene by influenza virus' * the whole document * --- -/--	1-10	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 3 March 1995	Examiner Andres, S
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons --- &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 94 11 5505

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	JOURNAL OF VIROLOGY, vol. 67, no.11, November 1993 pages 6659-6666, LI, S. ET AL. 'Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1' * the whole document *	1-10	
D,A	J VIROL 66 (7). 1992. 4331-4338, LI, X. ET AL. 'MUTATIONAL ANALYSIS OF THE PROMOTER REQUIRED FOR FLUENZA VIRUS VIRION RNA SYNTHESIS.'		
A	VIRUS RES 28 (2). 1993. 99-112, PICCONE, M. ET AL. 'MUTATIONAL ANALYSIS OF THE INFLUENZA VIRUS VRNA PROMOTER.'		
D,A	JOURNAL OF VIROLOGY, vol. 68, no.6, June 1994 pages 4092-4096, FODOR, E. ET AL. 'The influenza virus panhandle is involved in the initiation of transcription'		
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
Place of search THE HAGUE		Date of completion of the search 3 March 1995	Examiner Andres, S
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 (03.92) (P4/C01)